Innate Pharma SA

MARSEILLE, France I April 29, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. Nectin-4 targeting is validated by enfortumab vedotin (EV), an ADC with a monomethyl auristatin E (MMAE) payload, approved for urothelial carcinoma (UC), an indication with high Nectin-4 expression. However, EV discontinuation due to toxicity, disease relapse, or treatment ineligibility, along with its limited efficacy in tumors with lower Nectin-4 expression, underscores the need for a differentiated Nectin-4 ADC with improved therapeutic window and improved mechanisms of action. IPH4502 demonstrated anti-tumor activity in EV-resistant patient-derived xenograft (PDX) model with upregulation of multi-drug resistance protein 1 (MDR1), supporting its potential to overcome resistance mechanisms in EV-refractory disease. Beyond UC, IPH4502 also exhibited anti-tumor activity in preclinical models of triple-negative breast cancer, head and neck squamous cell carcinoma, and esophageal cancer, suggesting broader potential clinical applicability. In addition, in preclinical tumor models with low Nectin-4 expression, IPH4502 showed superior anti-tumor activity compared to a clinical-stage Nectin-4-exatecan ADC supported by higher internalization, cytotoxicity, and bystander killing effect. “ We are highly encouraged by these preclinical data, which suggest that IPH4502 has the potential to translate into improved clinical benefit in indications with unmet medical need. These findings also reinforce the rationale for our ongoing Phase 1 trial. We look forward to sharing initial clinical data in 2026 as the program advances, ” said Sonia Quaratino, Chief Medical Officer of Innate Pharma . IPH4502 is currently investigated in a Phase 1 trial in advanced solid tumors known to express Nectin-4 ( NCT06781983 ). The poster is available on Innate Pharma’s website . About IPH4502 IPH4502 is a differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, such as urothelial carcinoma, breast cancer, non-small cell lung cancer or gastro-intestinal tract cancer. IPH4502 is currently investigated in a Phase 1 trial in advanced solid tumors. The Phase 1 trial will assess the safety, tolerability, and preliminary efficacy of IPH4502 in different solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients. In preclinical models, IPH4502 demonstrates strong bystander killing effect, and efficient internalization, enabling a potent anti-tumor activity in models with various Nectin-4 expression levels. Additionally, IPH4502 shows efficacy in models resistant to MMAE-ADC. These results support its potential for development beyond UC and in cancer patients treated with MMAE-based ADCs. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate’s portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com . Follow us on LinkedIn and X . SOURCE: Innate Pharma

Sanofi has agreed to invest around 15 million euros ($17.1 million) in new shares of Innate Pharma.\n Sanofi is handing back a phase 2-stage natural killer (NK) cell engager and canceling another cancer trial as the Big Pharma refocuses its relationship with Innate Pharma from oncology to autoimmune indications.Sanofi had been assessing a CD123-targeting drug, known as SAR443579 or IPH6101, in a phase 1/2 study for relapsed or refractory acute myeloid leukemia. The Big Pharma unveiled data last year that showed complete responses among five out of 15 patients who received a dose of 1 mg/kg, with three patients demonstrating a “durable” complete responses of more than 10 months.SAR’579 has been in a phase 2 dose-expansion portion of the study for the past year, but Sanofi said this morning that it is handing the drug back to Innate. The two companies will “discuss a transition plan with regard to ongoing studies,” Sanofi explained in an April 23 release.SAR’579 was created with Innate’s NK cell engager platform, dubbed ANKET, and the biopharma will continue to collaborate with the French Big Pharma on a number of other drugs from this source. One of them is a BCMA-targeting NK cell engager called IPH6401, also known as SAR’514.When they signed their initial collaboration back in 2016, the plan was for Sanofi to investigate SAR’514 in multiple myeloma. But the company said Wednesday morning that it will now terminate a phase 1/2 study in this cancer indication and instead refocus the asset toward autoimmune disease.“We acknowledge Sanofi’s portfolio prioritization, and we are encouraged to see our ANKET platform being pursued in autoimmune indications,” Innate’s CEO Jonathan Dickinson said. “We will continue to evaluate, plan and execute next steps for our proprietary ANKET programs in oncology and beyond.” Sanofi also suggested that as part of the amendments to the 2016 agreement, the pharma has agreed to invest about 15 million euros ($17.1 million) in new shares of Innate. However, the exact size of the equity investment “will be determined on the basis of the ongoing market conditions, if they are satisfactory,” the drugmaker said.“We are very pleased that Sanofi has chosen to further strengthen our relationship through a potential strategic equity investment in the company,” Dickinson added in the same release. “This would further validate the innovation and scientific progress at Innate Pharma delivered by our research and development.”The two French companies also have a separate collaboration signed in 2022 to use the ANKET platform to target the glycoprotein B7-H3, which is overexpressed on various solid tumors. This deal is unaffected by today’s news, according to Sanofi.In all, Innate could still receive more than 1 billion euros ($1.1 billion) in R&D and commercial milestones from Sanofi should the various bets pay off.Sanofi has been undergoing a major pipeline shake-up in an effort to become “an immunoscience powerhouse,\" according to an internal letter obtained by Fierce Biotech last year.The Big Pharma has been on a spending spree to bolster its autoimmune and immunology pipeline, picking up bispecific antibodies for colitis and Crohn’s disease from Earendil Labs last week, while returning to Nurix earlier this month for a $480 million autoimmune deal comprising a degrader of a once-undruggable transcription factor. 

MARSEILLE, France I April 22, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announce review of their January 2016 Research Collaboration and License Agreement (the “2016 Agreement”) with Sanofi: As part of these discussions, Sanofi and Innate have agreed to a potential investment by Sanofi of up to €15M in new shares of Innate. The size and price of this equity investment will be determined on the basis of the ongoing market conditions, if they are satisfactory. The 2022 research collaboration and license agreement remain unchanged. “We are very pleased that Sanofi has chosen to further strengthen our relationship through a potential strategic equity investment in the company. This would further validate the innovation and scientific progress at Innate Pharma delivered by our research and development. We acknowledge Sanofi’s portfolio prioritization, and we are encouraged to see our ANKET ® platform being pursued in autoimmune indications. We will continue to evaluate, plan and execute next steps for our proprietary ANKET ® programs in oncology and beyond,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. SAR’579 (NCT05086315)/IPH6101 SAR’514/IPH6401: IPH62 and one additional target About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® ( A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate’s portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X . SOURCE: Innate Pharma